Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

@article{Tejpar2012AssociationOK,
  title={Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.},
  author={Sabine Tejpar and I. Atilla Çelik and Michael Schlichting and Ute Sartorius and C Carsten Bokemeyer and Eric Van Cutsem},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 29},
  pages={
          3570-7
        }
}
PURPOSE We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment. METHODS Associations between tumor KRAS mutation status (wild-type, G13D, G12V, or other mutations) and progression-free survival (PFS), survival, and response were investigated in pooled data from 1,378 evaluable patients from the CRYSTAL and OPUS studies. Multivariate analysis correcting for… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 149 CITATIONS, ESTIMATED 37% COVERAGE

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

Tamas Hickish, J. Christopher Cassidy, +11 authors Mark Harrison
  • European journal of cancer
  • 2014
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

  • Journal of Cancer Research and Clinical Oncology
  • 2013
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Personalized treatment for advanced colorectal cancer: KRAS and beyond

  • Cancer management and research
  • 2013
VIEW 3 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 12 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2011
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…